Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer February 26, 2024
First Refractory Gastric Cancer Patient Dosed in Ph 2 Trial with Allogeneic INKT Cell Therapy and Botensilimab and Balstilimab February 26, 2024
FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) February 26, 2024
First Patient Dosed in ALETA-001 Ph 1/2 Trial in Patients with R/R B-Cell Malignancies February 26, 2024
Supplemental BLA submitted to US FDA seeking approval of DARZALEX FASPRO)-based regimen for treatment of patients with transplant-eligible, newly diagnosed multiple myeloma February 26, 2024
Ph 3 PRESERVE 2 trial of Cosela in mTNBC to continue to final analysis following IDMC recommendation February 26, 2024
Type II Extension of Indication Application to the EMA Seeking Approval of RYBREVANT + Lazertinib, for 1L Treatment of Patients with EGFR-Mutated NSCLC February 26, 2024
EMA Validates Type II Variation Application for PADCEV (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for 1L Treatment of Advanced Bladder Cancer February 26, 2024
PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) Granted Priority Review by Japan’s MHLW for 1L Treatment of Advanced Bladder Cancer February 26, 2024
BLA for LYMPHIR™ (Denileukin Diftitox) For The Treatment Of Adults With R/R CTCL resubmitted February 26, 2024
U.S. and EU Regulatory Filings for Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable NSCLC accepted February 26, 2024
First Patient Dosed in Ph 1/2 Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors February 26, 2024
Dosing Initiated in Second Cohort of Ovarian Cancer FSHR-targeting CER-T Clinical Trial February 26, 2024
First Subject Dosed in Ph 1b/2 Study of Ampligen® + Imfinzi for the Treatment of Pancreatic Cancer February 26, 2024
REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer initiated February 26, 2024
First Patient Dosed in Ph 1b/2 Trial of Samuraciclib + Vepdegestrant in Patients with Advanced Breast Cancer February 26, 2024
Ph 2 Portion of ALKOVE-1 Trial for Patients with ALK+ve NSCLC and other Solid Tumors initiated February 26, 2024
